» Articles » PMID: 28936195

Diagnostic Yield and Accuracy of Different Metabolic Syndrome Criteria in Adult Patients with Epilepsy

Overview
Journal Front Neurol
Specialty Neurology
Date 2017 Sep 23
PMID 28936195
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Metabolic syndrome (MetS) is an emergent problem among patients with epilepsy. Here, we evaluate and compare the diagnostic yield and accuracy of different MetS criteria among adult patients with epilepsy to further explore the best strategy for diagnosis of MetS among patients with epilepsy.

Materials And Methods: Ninety-five epileptic adults from a tertiary epilepsy reference center were prospectively recruited over 22 weeks in a cross-sectional study. MetS was defined according to five international criteria used for the diagnosis of the condition [ATP3, American Association of Clinical Endocrinologists (AACE), International Diabetes Federation (IDF), AHA/NHLBI, and harmonized criteria]. Sensitivity, specificity, positive and negative predictive values (NPVs), and area under the receiver operating characteristic curve (ROC) curve were estimated for each criterion.

Results: In our sample, adult patients with epilepsy showed a high prevalence of obesity, hypertension, and diabetes. However, the prevalence of MetS was significantly different according to each criterion used, ranging from 33.7%, as defined by AACE, to 49.4%, as defined by the harmonized criteria ( < 0.005). IDF criteria showed the highest sensitivity [ = 95.5% (95% CI 84.5-99.4),  < 0.05] and AACE criteria showed the lowest sensitivity and NPV [ = 68.2% (95% CI 52.4-81.4),  < 0.05; NPV = 75.8% (95% CI 62.3-86.1),  < 0.05]. ROC curve for all criteria studied showed that area under curve (AUC) for IDF criterion was 0.966, and it was not different from AUC of harmonized criterion ( = 0.092) that was used as reference. On the other hand, the use of the other three criteria for MetS resulted in significantly lower performance, with AUC for AHA/NHLBI = 0.920 ( = 0.0147), NCEP/ATP3 = 0.898 ( = 0.0067), AACE = 0.830 ( = 0.00059).

Conclusion: Our findings suggest that MetS might be highly prevalent among adult patients with epilepsy. Despite significant variations in the yield of different criteria, the harmonized definition produced the highest prevalence rates and perhaps should be preferred. Correct evaluation of these patients might improve the rates of detection of MetS and foster primary prevention of cardiovascular events in this population.

Citing Articles

Exploring molecular mechanisms of exercise on metabolic syndrome: a bibliometric and visualization study using CiteSpace.

Wan K, Jin Y, Fan R, Xu Q, Li X, Yan H Front Endocrinol (Lausanne). 2024; 15:1408466.

PMID: 39290329 PMC: 11405195. DOI: 10.3389/fendo.2024.1408466.


Lifestyle Can Exert a Significant Impact on the Development of Metabolic Complications and Quality Life in Patients with Inflammatory Bowel Disease.

Garcia-Mateo S, Martinez-Dominguez S, Gargallo-Puyuelo C, Villarino M, Laredo De La Torre V, Gallego B Nutrients. 2023; 15(18).

PMID: 37764769 PMC: 10537893. DOI: 10.3390/nu15183983.


Prevalence of metabolic syndrome in patients with end-stage renal disease: a systematic review and meta-analysis.

Du Q, Jiang Y, Liu Y Int Urol Nephrol. 2023; 56(3):1057-1069.

PMID: 37740847 DOI: 10.1007/s11255-023-03790-z.


Metabolic syndrome and its associated factors among epileptic patients at Dessie Comprehensive Specialized Hospital, Northeast Ethiopia; a hospital-based comparative cross-sectional study.

Kassaw A, Endale H, Hunie Tesfa K, Molla M PLoS One. 2022; 17(12):e0279580.

PMID: 36580471 PMC: 9799290. DOI: 10.1371/journal.pone.0279580.


Association of Tourette Syndrome and Chronic Tic Disorder With Metabolic and Cardiovascular Disorders.

Brander G, Isomura K, Chang Z, Kuja-Halkola R, Almqvist C, Larsson H JAMA Neurol. 2019; 76(4):454-461.

PMID: 30640363 PMC: 6459125. DOI: 10.1001/jamaneurol.2018.4279.

References
1.
Reynolds E . The ILAE/IBE/WHO epilepsy global campaign history. International League Against Epilepsy. International Bureau for Epilepsy. Epilepsia. 2002; 43 Suppl 6:9-11. DOI: 10.1046/j.1528-1157.43.s.6.5.x. View

2.
Law M, Watt H, Wald N . The underlying risk of death after myocardial infarction in the absence of treatment. Arch Intern Med. 2002; 162(21):2405-10. DOI: 10.1001/archinte.162.21.2405. View

3.
Lakka H, Laaksonen D, Lakka T, Niskanen L, Kumpusalo E, Tuomilehto J . The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288(21):2709-16. DOI: 10.1001/jama.288.21.2709. View

4.
. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

5.
Einhorn D, Reaven G, Cobin R, Ford E, Ganda O, Handelsman Y . American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003; 9(3):237-52. View